Proposed trial: Safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents-rationale and protocol1

Biochemistry and Cell Biology

Volumn 93, Issue 5, 2015, Pages 522-530

  Wicklow, Brandy ^a,b   Wittmeier, Kristy ^a,b,c,d   Tjong, Geert W ^a,b   McGavock, Jonathon ^a,b   Robert, Marni ^d   Duhamel, Todd ^a,b   Dolinsky, Vernon W ^b,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Institute of Child Health   (Canada)

^c Center for Health Care Innovation   (Canada)

^d WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^e ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Adolescents; Non alcoholic fatty liver disease; Obesity; Steatosis; Type 2 diabetes

Indexed keywords

BODY FLUIDS; ENZYME INHIBITION; INSULIN; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; RESVERATROL; SAFETY ENGINEERING;

ADOLESCENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; STEATOSIS; TYPE-2 DIABETES;

DISEASES;

PLACEBO; RESVERATROL; STILBENE DERIVATIVE;

ADOLESCENT; ADULT; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART FUNCTION; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SERUM; STUDY DESIGN; DIETARY SUPPLEMENT; FEMALE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; ORAL DRUG ADMINISTRATION; OVERWEIGHT; PEDIATRIC OBESITY;

ADMINISTRATION, ORAL; ADOLESCENT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PEDIATRIC OBESITY; STILBENES;

EID: 84985920385     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0136     Document Type: Review

References (45)

1. Almeida L. Vaz-da-Silva M. Falcao A. Soares E. Costa R. Loureiro A.I. Fernandes-Lopes C. Rocha J.-F. Nunes T. Wright L. Soares-da-Silva P. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53 (Suppl 1): S7-S15. 10.1002/mnfr.200800177.
2. Baur J.A. Pearson K.J. Price N.L. Jamieson H.A. Lerin C. Kalra A. Prabhu V.V. Allard J.S. Lopez-Lluch G. Lewis K. Pistell P.J. Poosala S. Becker K.G. Boss O. Gwinn D. Wang M. Ramaswamy S. Fishbein K.W. Spencer R.G. Lakatta E.G. Le Couteur D. Shaw R.J. Navas P. Puigserver P. Ingram D.K. de Cabo R. Sinclair D.A. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444: 337-342. 10.1038/nature05354. 17086191.
3. Boocock D.J. Faust G.E.S. Patel K.R. Schinas A.M. Brown V.A. Ducharme M.P. Booth T.D. Crowell J.A. Perloff M. Gescher A.J. Steward W.P. Brenner D.E. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246-1252. 10.1158/1055-9965.EPI-07-0022.
4. Brasnyó P. Molnár G.A. Mohás M. Markó L. Laczy B. Cseh J. Mikolás E. Szijártó I.A. Mérei A. Halmai R. Mészáros L.G. Sumegi B. Wittmann I. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Brit. J. Nutr. 106: 383-389. 10.1017/S0007114511000316.
5. Brown V.A. Patel K.R. Viskaduraki M. Crowell J.A. Perloff M. Booth T.D. Vasilinin G. Sen A. Schinas A.M. Piccirilli G. Brown K. Steward W.P. Gescher A.J. Brenner D.E. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70: 9003-9011. 10.1158/0008-5472.CAN-10-2364.
6. Browning J.D. Szczepaniak L.S. Dobbins R. Nuremberg P. Horton J.D. Cohen J.C. Grundy S.M. Hobbs H.H. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40: 1387-1395. 10.1002/hep.20466.
7. Calabrese E.J. Mattson M.P. Calabrese V. 2010. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum. Exp. Toxicol. 29: 980-1015. 10.1177/0960327110383625. 21115559.
8. Chachay V.S. Macdonald G.A. Martin J.H. Whitehead J.P. O'Moore-Sullivan T.M. Lee P. Franklin M. Klein K. Taylor P.J. Ferguson M. Coombes J.S. Thomas G.P. Cowin G.J. Kirkpatrick C.M. Prins J.B. Hickman I.J. 2014. Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 12: 2092-2103. 10.1016/j.cgh.2014.02.024.
9. Crandall J.P. Oram V. Trandafirescu G. Reid M. Kishore P. Hawkins M. Cohen H.W. Barzilai N. 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. Ser. A, 67: 1307-1312. 10.1093/gerona/glr235.
10. D'Adamo E. Cali A.M.G. Weiss R. Santoro N. Pierpont B. Northrup V. Caprio S. 2010. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care, 33: 1817-1822. 10.2337/dc10-0284.
11. Dart A.B. Sellers E.A. Martens P.J. Rigatto C. Brownell M.D. Dean H.J. 2012. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care, 35: 1265-1271. 10.2337/dc11-2312.
12. Dart A.B. Martens P.J. Rigatto C. Brownell M.D. Dean H.J. Sellers E.A. 2014. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care, 37: 436-443. 10.2337/dc13-0954.
13. Deivanayagam S. Mohammed B.S. Vitola B.E. Naguib G.H. Keshen T.H. Kirk E.P. Klein S. 2008. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am. J. Clin. Nutr. 88: 257-262. 18689359.
14. Dolinsky V.W. Dyck J.R.B. 2011. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim. Biophys. Acta Mol. Basis Dis. 1812: 1477-1489. 10.1016/j.bbadis.2011.06.010.
15. Dolinsky V.W. Dyck J.R.B. 2014. Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature. Molecules, 19: 14919-14947. 10.3390/molecules190914919.
16. Dolinsky V.W. Rueda-Clausen C.F. Morton J.S. Davidge S.T. Dyck J.R. 2011. Continued postnatal administration of resveratrol prevents diet-induced metabolic syndrome in rat offspring born growth restricted. Diabetes, 60: 2274-2284. 10.2337/db11-0374.
17. Dolinsky V.W. Jones K.E. Sidhu R.S. Haykowsky M. Czubryt M.P. Gordon T. Dyck J.R.B. 2012. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J. Physiol. 590: 2783-2799. 10.1113/jphysiol.2012.230490. 22473781.
18. Fabbrini E. Magkos F. Mohammed B.S. Pietka T. Abumrad N.A. Patterson B.W. Okunade A. Klein S. 2009. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. 106: 15430-15435. 10.1073/pnas.0904944106.
19. Ghanim H. Sia C.L. Korzeniewski K. Lohano T. Abuaysheh S. Marumganti A. Chaudhuri A. Dandona P. 2011. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 96: 1409-1414. 10.1210/jc.2010-1812.
20. Jeon B.T. Jeong E.A. Shin H.J. Lee Y. Lee D.H. Kim H.J. Kang S.S. Cho G.J. Choi W.S. Roh G.S. 2012. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes, 61: 1444-1454. 10.2337/db11-1498.
21. Kim H. Taksali S.E. Dufour S. Befroy D. Goodman T.R. Petersen K.F. Shulman G.I. Caprio S. Constable R.T. 2008. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL. Magn. Reson. Med. 59: 521-527. 10.1002/mrm.21561.
22. Lagouge M. Argmann C. Gerhart-Hines Z. Meziane H. Lerin C. Daussin F. Messadeq N. Milne J. Lambert P. Elliott P. Geny B. Laakso M. Puigserver P. Auwerx J. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell, 127: 1109-1122. 10.1016/j.cell.2006.11.013. 17112576.
23. Larson-Meyer D.E. Heilbronn L.K. Redman L.M. Newcomer B.R. Frisard M.I. Anton S. Smith S.R. Alfonso A. Ravussin E. 2006. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care, 29: 1337-1344. 16732018.
24. Manna S.K. Mukhopadhyay A. Aggarwal B.B. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164: 6509-6519. 10843709.
25. McGavock J.M. Lingvay I. Zib I. Tillery T. Salas N. Unger R. Levine B.D. Raskin P. Victor R.G. Szczepaniak L.S. 2007. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation, 116: 1170-1175. 10.1161/CIRCULATIONAHA.106.645614. 17698735.
26. Muniyappa R. Lee S. Chen H. Quon M.J. 2008. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am. J. Physiol.: Endocrinol. Metab. 294: E15-E26. 10.1152/ajpendo.00645.2007.
27. Naqshbandi M. Harris S.B. Esler J.G. Antwi-Nsiah F. 2008. Global complication rates of type 2 diabetes in Indigenous peoples: A comprehensive review. Diabetes Res. Clin. Pract. 82: 1-17. 10.1016/j.diabres.2008.07.017. 18768236.
28. Nobili V. Manco M. Devito R. Di Ciommo V. Comparcola D. Sartorelli M.R. Piemonte F. Marcellini M. Angulo P. 2008. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology, 48: 119-128. 10.1002/hep.22336.
29. Pinhas-Hamiel O. Zeitler P. 2007. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet, 369: 1823-1831. 10.1016/S0140-6736(07)60821-6. 17531891.
30. Poulsen M.M. Vestergaard P.F. Clasen B.F. Radko Y. Christensen L.P. Stodkilde-Jorgensen H. Moller N. Jessen N. Pedersen S.B. Jorgensen J.O. 2013. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 62: 1186-1195. 10.2337/db12-0975.
31. Provencher S.W. 2001. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 14: 260-264. 11410943.
32. Qin F. Siwik D.A. Luptak I. Hou X. Wang L. Higuchi A. Weisbrod R.M. Ouchi N. Tu V.H. Calamaras T.D. Miller E.J. Verbeuren T.J. Walsh K. Cohen R.A. Colucci W.S. 2012. The polyphenols resveratrol and S17834 prevent the structural and functional sequelae of diet-induced metabolic heart disease in mice. Circulation, 125: 1757-1764; S1-S6. 10.1161/CIRCULATIONAHA.111.067801. 22388319.
33. Qureshi A.A. Guan X.Q. Reis J.C. Papasian C.J. Jabre S. Morrison D.C. Qureshi N. 2012. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis. 11: 76. 10.1186/1476-511X-11-76.
34. Rabol R. Petersen K.F. Dufour S. Flannery C. Shulman G.I. 2011. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc. Natl. Acad. Sci. U. S. A. 108: 13705-13709. 10.1073/pnas.1110105108.
35. Shaibi G.Q. Faulkner M.S. Weigensberg M.J. Fritschi C. Goran M.I. 2008. Cardiorespiratory fitness and physical activity in youth with type 2 diabetes. Pediatr. Diabetes, 9: 460-463. 10.1111/j.1399-5448.2008.00407.x.
36. Sullivan S. Kirk E.P. Mittendorfer B. Patterson B.W. Klein S. 2012. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology, 55: 1738-1745. 10.1002/hep.25548.
37. Timmers S. Konings E. Bilet L. Houtkooper R.H. van de Weijer T. Goossens G.H. Hoeks J. van der Krieken S. Ryu D. Kersten S. Moonen-Kornips E. Hesselink M.K. Kunz I. Schrauwen-Hinderling V.B. Blaak E.E. Auwerx J. Schrauwen P. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14: 612-622. 10.1016/j.cmet.2011.10.002.
38. Tomé-Carneiro J. Gonzálvez M. Larrosa M. Yáñez-Gascón M.J. García-Almagro F.J. Ruiz-Ros J.A. García-Conesa M.T. Tomás-Bárberan F.A. Espín J.C. 2012. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J Cardiol. 110: 356-363. 10.1016/j.amjcard.2012.03.030.
39. Vuppalanchi R. Cummings O.W. Saxena R. Ulbright T.M. Martis N. Jones D.R. Bansal N. Chalasani N. 2007. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J. Clin. Gastroenterol. 41: 206-210. 10.1097/01.mcg.0000225515.28536.3a.
40. Wicklow B.A. Wittmeier K.D.M. MacIntosh A.C. Sellers E.A.C. Ryner L. Serrai H. Dean H.J. McGavock J.M. 2012. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care, 35: 905-910. 10.2337/dc11-1754.
41. Wittmeier K.D.M. Wicklow B.A. MacIntosh A.C. Sellers E.A.C. Ryner L.N. Serrai H. Gardiner P.F. Dean H.J. McGavock J.M. 2012. Hepatic steatosis and low cardiorespiratory fitness in youth with type 2 diabetes. Obesity, 20: 1034-1040. 10.1038/oby.2011.379.
42. Yoshino J. Conte C. Fontana L. Mittendorfer B. Imai S. Schechtman K.B. Gu C. Kunz I. Rossi Fanelli F. Patterson B.W. Klein S. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16: 658-664. 10.1016/j.cmet.2012.09.015. 23102619.
43. Zhang H. Morgan B. Potter B.J. Ma L. Dellsperger K.C. Ungvari Z. Zhang C. 2010. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am. J. Physiol.: Heart Circ. Physiol. 299: H985-H994. 10.1152/ajpheart.00489.2010.
44. Zhu X. Liu Q. Wang M. Liang M. Yang X. Xu X. Zou H. Qiu J. 2011. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PloS one, 6: e27081.
45. Zimmet P. Alberti K.G.M.M. Shaw J. 2001. Global and societal implications of the diabetes epidemic. Nature, 414: 782-787. 10.1038/414782a. 11742409.